Abstract:

To investigate the drug resistance to first-line anti-tuberculosis drugs among tuberculosis patients in Jingzhou City, Hubei Province, a total of 2 681 samples preliminarily identified as Mycobacterium tuberculosis were tested with BACTEC MGIT 960 for 4 first-line anti-tuberculosis drugs (streptomycin:S, isoniazide:H, rifampicin:R and ethambutol:E). The results demonstrated that the total drug resistance rate was 28.87% (774/2681). The total drug resistance rates among all patients (from 2015 to 2019, 31.55% (147/466), 32.52% (159/489), 30.84% (165/535), 25.04% (151/603) and 25.85% (152/588), respectively) and among retreatment patients (from 2015 to 2019, 60.13% (92/153), 55.94% (80/143), 59.71% (83/139), 42.67% (64/150), 51.38% (56/109), respectively) both demonstrated a downward tendency over time, differences were statistically significant ( {\chi }_{\mathrm{trend}}^2 =12.716,P=0.013; {\chi }_{\mathrm{trend}}^2 =12.418,P=0.014).The total multi-drug resistance rate of isolates was 12.23% (328/2681), which were 5.49% (109/1987) and 31.56% (219/694) among newly treated and retreated patients respectively. The proportion of drug-resistant isolates from newly treated patients and multidrug-resistant isolates within all drug-resistant isolates (from 2015 to 2019, the former were 37.41% (55/147), 49.69% (79/159), 49.70% (82/165), 57.62% (87/151), 63.16% (96/152); the latter were 24.29% (17/70), 26.67% (16/60), 32.35% (22/68), 33.33% (21/63), 49.25% (33/67), respectively) all demonstrated an increasing tendency over time, differences were statistically significant ( {\chi }_{\mathrm{trend}}^2 =22.632,P<0.01; {\chi }_{\mathrm{trend}}^2 =11.466,P=0.022). The order of drugs with higher proportion of drug resistance were isoniazid (20.51% (550/2681)), streptomycin (18.99% (509/2681)), rifampicin (14.77% (396/2681)), ethambutol (7.83% (210/2681)) in sequence.

Key words: Tuberculosis, multi-drug resistant, Medicine sensitiveness test, Drug resistance monitoring, Small-area analysis